



## News Release

### **Suven to Present at Bio-Europe 2015 Partnering conference held during November 2 - 4, 2015 in Munich, Germany**

HYDERABAD, INDIA (Nov 02, 2015) – Several exciting new results and data presentations from Suven's portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at Bio-Europe 2015 in Munich, Germany, November 2- 4, 2015.

BIO-Europe® is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. BIO-Europe's partneringONE®, enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups

During BIO-Europe 2015 partnering conference, Suven lined up several face to face meetings with major Pharma, Biotech and financial companies to explore potential partnering and out licensing of the clinical candidates SUVN-502, SUVN-G3031, SUVN-D4010 and pre-clinical candidate SUVN-911.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

**Risk Statement:**

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*